• Symptom-related Screening for Early Detection of CTEPH.

  NCT03953560

  CompletedInterventionalNot ApplicableUpdated Mar 17, 2022
• CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients

  NCT03083093

  CompletedObservationalUpdated Apr 19, 2021
• The Prospective Risk Factor Evaluation & Discovery In CTEPH Study

  NCT03470207

  Unknown statusInterventionalNot ApplicableUpdated May 17, 2019
• Early Non-invasive Detection of CTEPH After Pulmonary Embolism

  NCT02555137

  CompletedObservationalUpdated Feb 9, 2021
• Symptom-driven Referral for Evaluation of Chronic Thromboembolic Disease or Pulmonary Hypertension in Patients With Previous Acute Pulmonary Embolism

  NCT03729492

  Unknown statusInterventionalNot ApplicableUpdated Nov 2, 2018
• Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH)

  NCT03719027

  CompletedInterventionalNot ApplicableUpdated May 3, 2024

ClinicalTrials.gov ID

NCT06865326

Lead Sponsor

Institute of Health Information and Statistics of the Czech RepublicOTHER_GOV

Overall Status

Recruiting

Study Type

Observational

Enrollment

500Estimated

Last Update Posted

Nov 21, 2025Actual

Start Date

Mar 7, 2025Actual

Primary Completion Date

May 31, 2026Estimated

Completion Date

Dec 1, 2026Estimated

Official Title

Early Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients After Acute Pulmonary Embolism

Brief Summary

The project is a national, prospective, multicenter, observational pilot project of screening CTEPH in pacients after APE in the Czech Republic. The main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Chronic tromboembolic pulmonary hypertesion in such a way as to ensure the maximum positive impact on the health of the population and high cost-effectiveness of the whole process.

Detailed Description

The project is a national, prospective, multicenter, observational pilot project of screening CTEPH in pacients after APE in the Czech Republic.

The global goal of the project is to develop, test and implement a uniform procedure for early detection of patients with CTEPH and to set up a process for their rapid referral to a specialized center that treats chronic thromboembolic pulmonary hypertension. The timeliness of the treatment set up has a significant impact on patient's future quality of life and eliminates the risk of subsequent complications or death.

The main objective of this activity is to validate the CTEPH screening process, which will benefit 500 patients in approximately 10 selected centres. Subsequently, patient flow from the cardiologist to a specialised pulmonary hypertension treatment centre will be ensured. The process will include a review and evaluation of the screening algorithm in patients in the pilot.

The project is supported by the European Social Fund (Operational Program Employment plus) and the state budget of the Czech Republic and is registered by the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22_005/0002007

• Chronic Pulmonary Thromboembolism

• Standardized CTEPH Screening Protocol

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age over 18 years

• Signed consent to participate in the project and GDPR

• Patients with an episode of acute pulmonary embolism in the last 3-12 months, with ongoing anticoagulation therapy:

  1. Patients with new-onset and ongoing or progressive dyspnea (min. NYHA II) after a pulmonary embolism episode or worsening of dyspnea after a pulmonary embolism episode compared to the status before the episode (at least 1 HYHA grade) or
  2. Asymptomatic patients after a pulmonary embolism episode and at least one of the following risk factors:

• ECHO evidence of severe PH at diagnosis of PE (PASP >60 mmHg)

• Antiphospholipid syndrome with triple positivity (presence of lupus anticoagulans + anti-beta-2-glycoprotein I (B2GPI) antibodies + anticardiolipin)

• Infected permanent venous inlets and cardiac pacing/defibrillation intravascular systems

• Presence of ventriculoatrial shunt for treatment of hydrocephalus

• Nonspecific intestinal inflammation (ulcerative colitis, Crohn's disease)

• History of splenectomy

• Myeloproliferative disorders

• Chronic osteomyelitis

Exclusion Criteria:

• Not agreeing to participate in the project
• Contraindications to treatment

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Institute of Health Information and Statistics of the Czech RepublicOTHER_GOV

Collaborators

General University Hospital, PragueOTHER

kucharj@seznam.cz420 723 465 691